A panel of FDA advisers will convene on March 20 to evaluate Abbott's MitraClip system for aortic valve repair. The company seeks to have the device approved for use in minimizing symptomatic mitral valve regurgitation in patients who are too weak to receive open-heart procedures.
FDA sets review date for Abbott's aortic valve repair system
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan